Physician profile
Chi C Shum
NPI 1033143003
$32,779.92
in general payments reported to CMS, 2019-2025
63 companies · $5,272 in 2025
The $5,272 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,121 · 2020: $4,335 · 2021: $4,369 · 2022: $4,300 · 2023: $5,588 · 2024: $5,795 · 2025: $5,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $527 · Honoraria: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,930.19 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $527.00 |
| Honoraria | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,305.50 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $3,827.59 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $3,739.23 | 2019-2025 | Vraylar, Qulipta, Synthroid |
| Glaxosmithkline, LLC. | $2,741.41 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,612.62 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $1,442.07 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,208.71 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $1,124.49 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $1,102.81 | 2022-2023 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $991.57 | 2019-2025 | Jardiance |
| Corium, LLC | $688.84 | 2022-2025 | Azstarys |
| Amgen INC. | $676.56 | 2019-2025 | Otezla, Repatha, Repatha |
| Amarin Pharma, INC. | $663.27 | 2019-2022 | |
| Neos Therapeutics, LP | $649.85 | 2019-2024 | Adzenys Xr-Odt |
| Gilead Sciences, INC. | $625.63 | 2019-2025 | Descovy |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chi Shum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.